Support Your Metabolism with Clinically-Studied Ingredients

Mitolyn — 6 plant-based nutrients to boost mitochondrial health, energy & natural fat burning.

★★★★★ 127,000+ customers · 90-day money-back guarantee

Dr. Martin Pollak, MD

Nephrology Boston, MA Male

NPI: 1720096738

Total Payments

$20.3M

2024 Payments

$2.66

Companies

Transactions

Medicare Patients

271

Medicare Billing

$29,016

Payment Breakdown by Category

Royalty/License$20.3M (99.9%)

Consulting$22,130 (0.1%)

Food & Beverage$480.16 (0.0%)

Education$2.66 (0.0%)

Payments by Nature

Nature of Payment	Amount	Transactions	Share
Royalty or License	$20.3M	7	99.9%
Consulting Fee	$22,130	10	0.1%
Food and Beverage	$480.16	17	0.0%
Education	$2.66	1	0.0%

Top Paying Companies

Company	Total	Records	Latest Year
Vertex Pharmaceuticals Incorporated	$20.3M	31	$0 (2023)
Merck Sharp & Dohme Corporation	$4,500	1	$0 (2018)
Janssen Research & Development, LLC	$61.55	1	$0 (2018)
Travere Therapeutics, Inc.	$39.01	2	$0 (2024)

Payment History by Year

Year	Amount	Transactions	Top Company
2024	$2.66	1	Travere Therapeutics, Inc. ($2.66)
2023	$2,557	4	Vertex Pharmaceuticals Incorporated ($2,521)
2022	$1,845	2	Vertex Pharmaceuticals Incorporated ($1,845)
2021	$18.8M	3	Vertex Pharmaceuticals Incorporated ($18.8M)
2020	$4,920	3	VERTEX PHARMACEUTICALS INCORPORATED ($4,920)
2019	$1.0M	8	VERTEX PHARMACEUTICALS INCORPORATED ($1.0M)
2018	$507,799	14	Vertex Pharmaceuticals Incorporated ($503,237)

All Payment Transactions

35 individual payment records from CMS Open Payments — Page 1 of 2

Date	Company	Product	Nature	Form	Amount	Type
03/15/2024	Travere Therapeutics, Inc.	—	Education	In-kind items and services	$2.66	General
11/03/2023	Vertex Pharmaceuticals Incorporated	—	Food and Beverage	In-kind items and services	$53.50	General
07/19/2023	Vertex Pharmaceuticals Incorporated	—	Consulting Fee	Cash or cash equivalent	$2,460.00	General
06/01/2023	Vertex Pharmaceuticals Incorporated	—	Food and Beverage	In-kind items and services	$7.64	General
05/27/2023	Travere Therapeutics, Inc.	—	Food and Beverage	In-kind items and services	$36.35	General
04/20/2022	Vertex Pharmaceuticals Incorporated	—	Consulting Fee	Cash or cash equivalent	$820.00	General
03/02/2022	Vertex Pharmaceuticals Incorporated	—	Consulting Fee	Cash or cash equivalent	$1,025.00	General
12/20/2021	Vertex Pharmaceuticals Incorporated	—	Royalty or License	Cash or cash equivalent	$15,000,000.00	General
12/20/2021	Vertex Pharmaceuticals Incorporated	—	Royalty or License	Cash or cash equivalent	$3,750,000.00	General
06/09/2021	Vertex Pharmaceuticals Incorporated	—	Consulting Fee	Cash or cash equivalent	$1,435.00	General
12/18/2020	VERTEX PHARMACEUTICALS INCORPORATED	—	Consulting Fee	Cash or cash equivalent	$1,230.00	General
09/02/2020	VERTEX PHARMACEUTICALS INCORPORATED	—	Consulting Fee	Cash or cash equivalent	$1,230.00	General
06/10/2020	VERTEX PHARMACEUTICALS INCORPORATED	—	Consulting Fee	Cash or cash equivalent	$2,460.00	General
11/06/2019	VERTEX PHARMACEUTICALS INCORPORATED	—	Consulting Fee	Cash or cash equivalent	$3,895.00	General
09/18/2019	Vertex Pharmaceuticals Incorporated	—	Royalty or License	Cash or cash equivalent	$500,000.00	General
06/24/2019	VERTEX PHARMACEUTICALS INCORPORATED	—	Food and Beverage	In-kind items and services	$58.00	General
06/24/2019	VERTEX PHARMACEUTICALS INCORPORATED	—	Food and Beverage	In-kind items and services	$39.00	General
06/24/2019	VERTEX PHARMACEUTICALS INCORPORATED	—	Food and Beverage	In-kind items and services	$26.00	General
06/24/2019	VERTEX PHARMACEUTICALS INCORPORATED	—	Food and Beverage	In-kind items and services	$26.00	General
05/15/2019	Vertex Pharmaceuticals Incorporated	—	Royalty or License	Cash or cash equivalent	$500,000.00	General
03/28/2019	Vertex Pharmaceuticals Incorporated	—	Food and Beverage	In-kind items and services	$9.67	General
12/08/2018	Vertex Pharmaceuticals Incorporated	—	Royalty or License	Cash or cash equivalent	$125,000.00	General
11/14/2018	Vertex Pharmaceuticals Incorporated	—	Food and Beverage	In-kind items and services	$10.36	General
11/01/2018	Vertex Pharmaceuticals Incorporated	—	Food and Beverage	In-kind items and services	$13.08	General
11/01/2018	Vertex Pharmaceuticals Incorporated	—	Food and Beverage	In-kind items and services	$11.34	General

1 2 »

Medicare Billing by Year

Year	Procedures	Beneficiaries	Services	Submitted	Medicare Paid
2023	3	50	70	$17,686	$4,934
2022	3	44	57	$15,182	$3,987
2021	3	44	60	$13,939	$3,761
2020	5	133	243	$61,990	$16,334

Total Patients

271

Total Services

430

Medicare Billing

$29,016

Procedure Codes

All Medicare Procedures & Services

14 procedure records from CMS Medicare Utilization

HCPCS	Description	Setting	Year	Patients	Services	Charges	Medicare Paid	Ratio
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	Facility	2023	21	39	$9,087	$2,613	28.8%
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	Facility	2023	15	15	$6,615	$1,651	25.0%
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	Facility	2023	14	16	$1,984	$669.92	33.8%
99222	Initial hospital inpatient care per day, typically 50 minutes	Facility	2022	17	17	$7,497	$1,965	26.2%
99232	Follow-up hospital inpatient care per day, typically 25 minutes	Facility	2022	15	25	$5,825	$1,526	26.2%
99231	Follow-up hospital inpatient care per day, typically 15 minutes	Facility	2022	12	15	$1,860	$495.74	26.7%
99222	Initial hospital inpatient care, typically 50 minutes per day	Facility	2021	15	15	$6,615	$1,779	26.9%
99232	Subsequent hospital inpatient care, typically 25 minutes per day	Facility	2021	11	16	$3,728	$1,008	27.0%
99231	Subsequent hospital inpatient care, typically 15 minutes per day	Facility	2021	18	29	$3,596	$974.40	27.1%
99232	Subsequent hospital inpatient care, typically 25 minutes per day	Facility	2020	44	86	$20,468	$5,391	26.3%
90945	Dialysis procedure including one evaluation	Facility	2020	16	62	$17,794	$4,704	26.4%
99222	Initial hospital inpatient care, typically 50 minutes per day	Facility	2020	27	28	$12,712	$3,338	26.3%
99231	Subsequent hospital inpatient care, typically 15 minutes per day	Facility	2020	32	46	$5,934	$1,565	26.4%
90935	Hemodialysis procedure with one physician evaluation	Facility	2020	14	21	$5,082	$1,336	26.3%

About Dr. Martin Pollak, MD

Dr. Martin Pollak, MD is a Nephrology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720096738.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Martin Pollak, MD has received a total of $20.3M in payments from pharmaceutical and medical device companies, with $2.66 received in 2024. These payments were reported across 35 transactions from 4 companies. The most common payment nature is "Royalty or License" ($20.3M).

As a Medicare-enrolled provider, Pollak has provided services to 271 Medicare beneficiaries, totaling 430 services with total Medicare billing of $29,016. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.

16,000 Woodworking Plans

Step-by-step blueprints for any project. Beginner to expert.

Detailed schematics Cutting lists & materials Lifetime access — $67

★★★★★ 60-day guarantee

Get Instant Access

Practice Information

Specialty Nephrology
Location Boston, MA
Active Since 08/04/2006
Last Updated 09/29/2011
Taxonomy Code 207RN0300X
Entity Type Individual
NPI Number 1720096738

Products in Payments

INVOKANA (Drug) $61.55

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.